UrSure Ships World’s First Point of Care Adherence Test for Researchers
BOSTON, January 21, 2020 —
UrSure, an HIV prevention company, today announced that the company has shipped the first order of their novel Point of Care PrEP adherence test to a domestic researcher. UrSure makes diagnostic tests that measure and improve adherence to HIV medications, including both PrEP and HIV treatment.
To date, UrSure has run over 5,000 of its novel lab tests in 11 states across the United States. Concurrently, they have been developing a point of care (POC) version of their test that delivers the same adherence data to the clinician and patient within 10 minutes (see test featured in this 2 minute video).
“Our point of care test will allow the provider to actually counsel the patient on their adherence results during the clinical visit, which is a huge advancement over a lab-based test requiring days to return a result” said Dr. Giffin Daughtridge, co-founder and CEO of UrSure. “Our point of care test is inexpensive, doesn’t require lab infrastructure, and is easy to use allowing for global scale up. It looks and works just like a pregnancy test.”
UrSure’s point of care PrEP adherence test device
“UrSure’s mission is to prevent avoidable infections. HIV is now an entirely avoidable infection, and with improved adherence to PrEP, we can eradicate this disease,” added Dr. Daughtridge.
Looking forward, UrSure is working towards receiving FDA clearance for its point of care test so that it can be used commercially by any clinics. In the meantime, UrSure will continue providing this test for research use in studies worldwide. To date, UrSure has over 30 trials contracted to use their point of care test.